Back to Journals » Drug Design, Development and Therapy » Volume 8

Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study

Authors Kim S, Lee J, Shin D, Lim KS, Kim YS, Jang I, Yu K

Received 3 June 2014

Accepted for publication 27 June 2014

Published 6 October 2014 Volume 2014:8 Pages 1723—1731


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

Seokuee Kim,1 Jongtae Lee,1 Donghoon Shin,1 Kyoung Soo Lim,1 Yon Su Kim,2 In-Jin Jang,1 Kyung-Sang Yu1

1Department of Clinical Pharmacology and Therapeutics, 2Division of Nephrology, Department of Internal Medicine, Seoul National University College of Medicine and Hospital, Seoul, Korea

Background: Fimasartan is a novel angiotensin II receptor blocker. Fimasartan is mainly eliminated via biliary excretion, and its urinary elimination is less than 3%.
Objective: Based on guidance from the United States Food and Drug Administration, a reduced pharmacokinetic (PK) study was conducted to evaluate the effect of renal function on the PK of fimasartan in patients with renal impairment and healthy volunteers.
Methods: A single centre, single-dose, open-label, healthy volunteer controlled trial was conducted in patients with renal impairment (RI) (estimated glomerular filtration rate lower than 30 mL/min/1.73 m2) and age-, weight- and sex-matched healthy volunteers (estimated glomerular filtration rate higher than 90 mL/min/1.73 m2). All participants received a single oral dose of fimasartan 120 mg, after which serial blood sampling for PK evaluation was conducted. Noncompartmental PK analysis of fimasartan was performed. A mixed-effects model approach was used to identify significant covariates and PK parameters.
Results: Sixteen subjects were enrolled (8 healthy volunteers and 8 RI patients). The maximum plasma concentrations and areas under the plasma concentration curves of the RI patients were higher than those of the healthy volunteers, with geometric mean ratios of 1.87 and 1.73, respectively. The relative bioavailability of fimasartan from the population PK analysis was 77% higher in the RI patients than in the healthy volunteers.
Conclusion: The increased drug exposure of fimasartan in RI patients was explained by the increased relative bioavailability. This result can be explained from our knowledge concerning alterations in PK related to renal function.

Keywords: renal impairment, fimasartan, pharmacokinetics, safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]